Last reviewed · How we verify
Glycyrrhetinic Acid
At a glance
| Generic name | Glycyrrhetinic Acid |
|---|---|
| Sponsor | Shandong University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Glycyrrhetinic Acid and Acute Irritant Dermatitis (NA)
- Enoxolone in Major Depression - Biomarker-outcome Relationship (PHASE1, PHASE2)
- The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia (PHASE2)
- Effectiveness of Enoxolone on Oral Conditions of Patients With Periodontal Surgery (NA)
- To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue (PHASE1, PHASE2)
- Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II (PHASE2)
- The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia (PHASE2)
- Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glycyrrhetinic Acid CI brief — competitive landscape report
- Glycyrrhetinic Acid updates RSS · CI watch RSS
- Shandong University portfolio CI